Phase II proof of concept trial for APG 101 (Apogenix) is confirmed for Glioblastoma Multiforme

Apogenix announced the figures that confirm that the primary objective of its Phase II proof-of-concept trial investigating its lead product, APG101, as a second line treatment of Glioblastoma Multiforme (GBM), had been met, The company expects to unveil overall survival data from the study in the fourth quarter of 2012.In March 2012 the company reported that the primary objective of its 84-patient trial, which was to increase the percentage of patients reaching six-month-rate of progression-free survival (PFS6) by 100%, had been "exceeded substantially". Apogenix is looking for a partner to further develop the drug.